Compare American Express Co (AXP) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs BioNTech SE - ADR — how do they compare? American Express Co trades at $359.47 (market cap $242.27B), while BioNTech SE - ADR trades at $90.34 (market cap $22.86B). The key difference: American Express Co is far larger — about 10.6× BioNTech SE - ADR's market cap, and American Express Co pays a 1.07% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AXP | BNTX | |
|---|---|---|
Market Cap | $242.27B | $22.86B |
Sector | Financials | Health |
52-Week High | $384.82 | $119.34 |
52-Week Low | $292.27 | $83.89 |
Dividend Yield | 1.07% | — |
Enterprise Value | — | $6.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXP trades at $354.43, up 1.1% today, with a bullish technical signal from moving averages and support at $352. The company reported strong Q1 2026 earnings of $4.28 per share, beating estimates, with revenue reaching $72.23 billion in 2025. Recent news highlights AI investments and a new headquarters, while analyst consensus is a $373.62 price target with 40% buy ratings.
Outlook remains positive driven by revenue growth and premium cardholder expansion, but risks include economic sensitivity and rising debt levels. The stock offers potential upside to consensus targets, supported by institutional confidence and operational momentum, though investors should monitor spending trends and interest rate impacts.
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
